Klin Farmakol Farm. 2003;17(3):186-187

Léčba hypertenze u nemocných s ICHS - STUDIE INVEST

Jiří Vítovec1, doc. MUDr. Jindřich ©pinar CSc2
1 I. interní kardioangiologická klinika FN u sv. Anny v Brně
2 II. interní klinika FN u sv. Anny LF MU, Brno

Studie INVEST ukázala ľe kombinace verapamilu a trandolparilu je vhodnou alternativou betablokátoru a diuretika u nemocných s hypertenzí a ICHS.

Keywords: hypertension, CAD, combination therapy.

Published: December 31, 2003  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vítovec J, ©pinar J. Léčba hypertenze u nemocných s ICHS - STUDIE INVEST. Klin Farmakol Farm. 2003;17(3):186-187.

Studie INVEST ukázala ľe kombinace verapamilu a trandolaprilu je vhodnou alternativou betablokátoru a diuretika u nemocných s hypertenzí a ICHS.

Treatment of hypertension and ischemic heart disease - study invest

Results of study INVEST presented in hypertensive with CAD, verapamil and trandolapril were efective alternative to betablockers and diuretics.

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Horký K, Widimský J, Cífková R, Widimský J Jr. Doporučení diagnostických a léčebných postupů u arteriální hypertenze (verze 2000). Cor Vasa 2001; 43 :K6-K14.
    2. ©pinar J, Vítovec J, Zicha J a kol. Hypertenze - diagnostika a léčba. Grada Publishing 1999 228 s.
    3. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413-2146. Go to original source...
    4. Zanchetti A for the guidelines committee: 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. Journal of Hypertension 2003; 21: 1011-1023. Go to original source... Go to PubMed...
    5. The ALLHAT Officers ond Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in in high-risk hypertensive patients randomised to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic; the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997. Go to original source... Go to PubMed...
    6. Chobanian AV. JNC 7 Express. NIH publication 2003; 03-5233: 1-52.
    7. Vítovec J, ©pinar J. Hypertension and combination drug therapy. Cor Vasa 2000; 42: 461-465.
    8. Widimský J, Dzúrik E. Studie TEAM - studie účinnosti a snáąenlivosti léčby esenciální hypertenze fixní kombinací trandolaprilu a verapamilu. Vnitřní lékařství 1998; 44: 326-331. Go to PubMed...
    9. Pepine CJ for the INVEST Group. Outcomes from randomized trial of a calcium antagonists and non calcium antagonist blood pressure treatment strategy in patients with coronary artery disease: The INternational VErapamil-trandolapril STudy (INVEST). ACC Chicago Meeting, 2. 4. 2003, Late-Breaking Clinical Trials III. Go to original source...
    10. ©pinar J, Vítovec J, Kubecová L, Pařenica J. Klinické studie v kardiologii. Grada 2001: 485 s.
    11. The DAVIT II investigators.DAVIT II: Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II- Davit II). Am J Cardiol 1990; 66: 779-785. Go to original source... Go to PubMed...
    12. De Simone A, De Paquale M, De Matteis C, et al. Verapamil Plus Antiarrhytmic drugs Reduce Atrial Fibrillation recurrences after an eletrical cardioversion (VEPARAF Study). Eur Heart J 2003; 24: 1425-1429. Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.